Name: COMPUGEN LTD (CGEN) Stock
Brand: COMPUGEN LTD
Rating: 4.5 (3 reviews)

CGEN Latest News, Press Relases and Analysis

All

Press Releases

24 days ago - By: Zacks Investment Research - Mentions: BHST

Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates

24 days ago - By: Compugen Ltd.

Compugen Reports Third Quarter 2025 Results

a month ago - By: Zacks Investment Research - Mentions: CERT

Certara, Inc. (CERT) Q3 Earnings Surpass Estimates

a month ago - By: Zacks Investment Research - Mentions: VRTX

Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates

2 months ago - By: Compugen Ltd.

Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025

2 months ago - By: Compugen Ltd.

Compugen to Present at SITC 2025

3 months ago - By: Compugen Ltd.

Compugen to Present Research at the Single Cell Genomics 2025 Conference

3 months ago - By: Compugen Ltd.

Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

4 months ago - By: Compugen Ltd.

Compugen Reports Second Quarter 2025 Results

24 days ago - By: Benzinga - Mentions: OGN TACT IMDX QRHC ...

Earnings Scheduled For November 10, 2025

a month ago - By: Compugen Ltd.

Compugen to Participate in Stifel 2025 Healthcare Conference

a month ago - By: Compugen Ltd.

Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025

4 months ago - By: Benzinga - Mentions: OEC VTLE DIN INSE ...

Earnings Scheduled For August 6, 2025

2 months ago - By: ACCESS Newswire - Mentions: JG GNPX COE GCTK ...

Q3 Virtual Investor Summit: On-Demand Presentations Now Available

3 months ago - By: ACCESS Newswire - Mentions: UXIN JG PRSO SPCB ...

Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free

4 months ago - By: Zacks Investment Research - Mentions: CLSD

Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates

4 months ago - By: Compugen Ltd.

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025

7 months ago - By: Compugen Ltd.

Compugen Reports First Quarter 2025 Results

7 months ago - By: Compugen Ltd.

Compugen Announces Leadership Transitions Effective September 2025

7 months ago - By: Compugen Ltd.

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

5 months ago - By: Compugen Ltd.

Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer

6 months ago - By: Compugen Ltd.

Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

7 months ago - By: Zacks Investment Research - Mentions: AFMD

Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates

7 months ago - By: Zacks Investment Research - Mentions: FBIO

Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: Zacks Investment Research - Mentions: BRTX

Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates

8 months ago - By: Compugen Ltd.

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

9 months ago - By: Compugen Ltd.

Compugen Reports Fourth Quarter and Full Year 2024 Results

10 months ago - By: Compugen Ltd.

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

7 months ago - By: Zacks Investment Research - Mentions: RGNX

Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates

7 months ago - By: Zacks Investment Research - Mentions: MCK

McKesson (MCK) Tops Q4 Earnings Estimates

9 months ago - By: Compugen Ltd.

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

10 months ago - By: Compugen Ltd.

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

a year ago - By: Compugen Ltd.

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

a year ago - By: Compugen Ltd.

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

COMPUGEN LTD (CGEN) Stock News

CGEN Latest News, Press Relases and Analysis